PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa

Guo Bao Tian, Jennifer M. Adams-Haduch, Tatiana Bogdanovich, Hong Ning Wang, Yohei Doi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

Original languageEnglish
Pages (from-to)2710-2713
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number6
DOIs
Publication statusPublished - 01-06-2011
Externally publishedYes

Fingerprint

Pseudomonas aeruginosa
Aztreonam
Carbapenems
Ceftazidime
Cefotaxime
United Arab Emirates
Stenotrophomonas maltophilia
Sulbactam
Clavulanic Acid
Hospitalization
Plasmids
Amino Acids
Enzymes
Genes
cefepime

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tian, Guo Bao ; Adams-Haduch, Jennifer M. ; Bogdanovich, Tatiana ; Wang, Hong Ning ; Doi, Yohei. / PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 6. pp. 2710-2713.
@article{2fc3f1f67c984ec686bcddb89891b048,
title = "PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa",
abstract = "A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41{\%} amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.",
author = "Tian, {Guo Bao} and Adams-Haduch, {Jennifer M.} and Tatiana Bogdanovich and Wang, {Hong Ning} and Yohei Doi",
year = "2011",
month = "6",
day = "1",
doi = "10.1128/AAC.01660-10",
language = "English",
volume = "55",
pages = "2710--2713",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. / Tian, Guo Bao; Adams-Haduch, Jennifer M.; Bogdanovich, Tatiana; Wang, Hong Ning; Doi, Yohei.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 6, 01.06.2011, p. 2710-2713.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa

AU - Tian, Guo Bao

AU - Adams-Haduch, Jennifer M.

AU - Bogdanovich, Tatiana

AU - Wang, Hong Ning

AU - Doi, Yohei

PY - 2011/6/1

Y1 - 2011/6/1

N2 - A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

AB - A novel extended-spectrum β-lactamase (ESBL) was identified in a Pseudomonas aeruginosa clinical isolate obtained from a patient admitted to a hospital in Pennsylvania in 2008. The patient had a prolonged hospitalization in a hospital in Dubai, United Arab Emirates, before being transferred to the United States. The novel ESBL, designated PME-1 (Pseudomonas aeruginosa ESBL 1), is a molecular class A, Bush-Jacoby-Medeiros group 2be enzyme and shared 50, 43, and 41% amino acid identity with the L2 β-lactamase of Stenotrophomonas maltophilia, CTX-M-9, and KPC-2, respectively. PME-1 conferred clinically relevant resistance to ceftazidime, cefotaxime, cefepime, and aztreonam in P. aeruginosa PAO1 but not to carbapenems. Purified PME-1 showed good hydrolytic activity against ceftazidime, cefotaxime, and aztreonam, while activity against carbapenems and cefepime could not be measured. PME-1 was inhibited well by β-lactamase inhibitors, including clavulanic acid, sulbactam, and tazobactam. The blaPME-1 gene was carried by an approximately 9-kb plasmid and flanked by tandem ISCR24 elements.

UR - http://www.scopus.com/inward/record.url?scp=79956292854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956292854&partnerID=8YFLogxK

U2 - 10.1128/AAC.01660-10

DO - 10.1128/AAC.01660-10

M3 - Article

VL - 55

SP - 2710

EP - 2713

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -